The US is the bigger HIV Drugs market: $12.6 Bn against $546 Mn in 2023, about 23 times as large.
India grows faster: 8.8% a year, against 3.8%. The gap still grows from $12.1 Bn to $17 Bn by 2033.
Clinical research: 506 active trials in the US, 8 in India.
| Measure |  US |  India |
|---|---|---|
| Market size, 2023 | $12.6 Bn | $546 Mn |
| Market size, 2033 projected | $18.3 Bn | $1.3 Bn |
| Growth a year (CAGR) | 3.8% | 8.8% |
| Money added, 2023–2033 | $5.7 Bn | $723 Mn |
| Share of the world market | 42% | 1.8% |
| Size rank of 24 countries | #1 | #12 |
| Market per person, 2023 | $37 | $0.37 |
| Active clinical trials | 506 | 8 |
| New HIV infections people (WHO) | – | 60,000 2025 |
| Full report | US report | India report |
Year by year, 2023 to 2033
US India · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in HIV Drugs, US or India?
The US is the bigger HIV Drugs market: $12.6 Bn against $546 Mn in 2023, about 23 times as large.
Which grows faster in HIV Drugs, US or India?
India grows faster: 8.8% a year, against 3.8%. The gap still grows from $12.1 Bn to $17 Bn by 2033.
More HIV Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Health figures: WHO. Population: World Bank.